
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc. has demonstrated a robust financial performance, with international osteoarthritis (OA) pain revenue increasing by 21% compared to the previous year, supported by favorable order timing. The company’s regenerative solutions segment experienced a notable 25% growth, largely attributed to the Integrity patch, which has newly received 510K clearances for various applications, enhancing its market potential. Furthermore, Anika's strong fourth quarter exceeded expectations, featuring a free cash flow of $5 million, significantly outperforming prior estimates and indicating a strong trajectory for revenue growth as the company plans to increase procedures and revenue substantially by 2025.
Bears say
Anika Therapeutics reported a revenue decline of 5.9% year-over-year, generating $27.8 million, falling short of revenue and adjusted EBITDA expectations while achieving only modest success in cash generation. The company faces ongoing challenges with gross margins, reporting 56% due to production yield issues, and anticipates a significant revenue decline of 16-20% in its OEM channel, primarily driven by price pressures in the U.S. Additionally, the failure of its pivotal FastTrack trial for Hyalofast raises concerns about future product efficacy and market competitiveness, further contributing to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares